Abstract
Rheumatoid arthritis (RA), a prototypical immune-mediated inflammatory disease, is now definitely recognized to increase cardiovascular morbidity and mortality, irrespective of established classical risk factors. The chronic inflammatory state, a hallmark of RA, is increasingly considered to be a driving force for accelerated atherogenesis. Consequently, aggressive control of RA disease activity has been suggested to be instrumental for cardiovascular risk reduction. Currently, statins are the cornerstone of cardiovascular risk-reducing strategies. Apart from their lipid-lowering capacity, statins also exert immune-modulatory effects, which therefore may be of dual benefit in RA patients. Yet guidelines for optimal cardiovascular risk reduction in patients with RA are lacking, largely owing to the absence of randomized, clinical trial data. In this review, we focus on the pathophysiology and observational evidence of cardiovascular risk in RA, as well as the need to adjust currently employed cardiovascula...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.